All Updates

All Updates

icon
Filter
M&A
Certara acquires Chemaxon for undisclosed amount to increase predictive abilities in drug discovery
AI Drug Discovery
Jul 9, 2024
This week:
Partnerships
Sheeva.AI and P97 Networks partner for in-car payment solutions at fuel stations
Auto Tech
Today
Product updates
Food Cycle Science launches 'Food Cycler Eco 3,' a household food waste processing bin
Food Waste
Yesterday
Partnerships
Von Holzhausen and Herman Miller partner to launch plant-based leather Eames Chair
Bio-based Materials
Yesterday
Partnerships
Volvo Cars partners with Beijing Shougang and Zhejiang Yiyun for automotive steel recycling
Waste Recovery & Management Tech
Yesterday
Funding
LanzaJet receives strategic investment from Airbus
Carbon Capture, Utilization & Storage (CCUS)
Yesterday
Funding
LanzaJet receives strategic investment from Airbus
Alternative Energy
Yesterday
Partnerships
Odie Pet Insurance partners with Insuritas to offer pet coverage through financial institutions
Pet Care Tech
Yesterday
Partnerships
Odie Pet Insurance partners with Insuritas to offer pet coverage through financial institutions
InsurTech: Personal Lines
Yesterday
M&A
Applied Systems acquires Planck for undisclosed sum to expand AI capabilities
InsurTech: Infrastructure
Yesterday
Product updates
Monzo launches pension consolidation product
Neobanks
Yesterday
AI Drug Discovery

AI Drug Discovery

Jul 9, 2024

Certara acquires Chemaxon for undisclosed amount to increase predictive abilities in drug discovery

M&A

  • Pennsylvania-based pharmaceutical company Certara has entered a definitive agreement to acquire cheminformatics software provider Chemaxon for an undisclosed sum.

  • Post-acquisition, Certara plans to combine its technology with Chemaxon's to enhance prediction and analytical capabilities in drug discovery. The company aims to offer a comprehensive data and predictive analytics platform to improve decision-making from discovery through commercialization in the life sciences sector.

  • Certara specializes in providing software products and technology-enabled services, including AI-powered solutions to the pharmaceutical sector. The company's focus is on model-informed drug development, offering solutions that predict pharmacokinetics and pharmacodynamics through software services such as Simcyp Simulator, which predicts drug behavior within the human body, and Phoenix WinNonlin IVIV for in vitro-in vivo correlation (IVIVC) studies.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.